米非司酮联合桂枝茯苓胶囊治疗子宫肌瘤疗效及对血流分级的影响

Effect of mifepristone combined with Guizhi Fuling Capsule on hysteromyoma and blood flow classification

目的探究与分析米非司酮联合桂枝茯苓胶囊治疗子宫肌瘤疗效及对血流分级的影响。方法选取78例子宫肌瘤患者,采用随机数字表法分为对照组与研究组,各39例。对照组采用米非司酮治疗,研究组在对照组基础上联合桂枝茯苓胶囊治疗。对比两组临床疗效、治疗前后临床指标、激素指标、血清人附睾分泌蛋白4(HE_(4))、血清癌抗原125(CA125)水平、血流分级及治疗期间不良反应发生情况。结果研究组总有效率为92.31%,明显高于对照组的74.36%,差异有统计学意义(P<0.05)。治疗前,两组子宫体积、肌瘤体积、雌激素(E_(2))、卵泡刺激素(FSH)、孕酮(P)及促黄体生成素(LH)水平对比,差异无统计学意义(P>0.05);治疗后,两组子宫体积及肌瘤体积均小于治疗前,E_(2),FSH、P及LH水平低于治疗前,且研究组子宫体积、肌瘤体积均小于对照组,E_(2)、FSH、P及LH水平均低于对照组,差异有统计学意义(P<0.05)。治疗前,两组血清HE_(4)、CA125水平对比,差异无统计学意义(P>0.05);治疗后,两组血清HE_(4)、CA125水平均低于治疗前,且研究组明显低于对照组,差异具有统计学意义(P<0.05)。治疗前,两组血流分级对比,差异无统计学意义(P>0.05);治疗后,研究组血流分级明显优于对照组,差异有统计学意义(P<0.05)。两组治疗期间均未出现明显的不良反应,肝、肾功能及血常规指标均正常。结论米非司酮联合桂枝茯苓胶囊治疗子宫肌瘤疗效确切,可改善激素水平及血流指标,降低癌变风险,且治疗期间未增加不良反应,安全性较高,值得临床推广与应用。

Objective To explore and analyze the efficacy of mifepristone combined with Guizhi Fuling Capsule in the treatment of hysteromyoma and its effect on blood flow classification.Methods 78 patients with hysteromyoma were randomly divided into control group and study group with 39 cases in each group.The control group was treated with mifepristone,and the study group was treated with Guizhi Fuling Capsule on the basis of the control group.The clinical efficacy,clinical indexes,hormone indexes,serum human epididymal secretory protein 4(HE_(4))and serum cancer antigen 125(CA125),blood flow classification and adverse reactions during treatment were compared between the two groups.Results The total effective rate of the study group was 92.31%,which was significantly higher than 74.36% of the control group(P<0.05).Before treatment,there was no significant difference in uterine volume,myoma volume,estrogen(E_(2)),follicle stimulating hormone(FSH),progesterone(P)and luteinizing hormone(LH)levels between the two groups(P>0.05);After treatment,the uterine volume and leiomyoma volume of the two groups were smaller than those before treatment,and the E_(2),FSH,P and LH levels were lower than those before treatment.The uterine volume and leiomyoma volume of the study group were smaller than those of the control group,and the E_(2),FSH,P and LH levels were lower than those of the control group.The difference was statistically significant(P<0.05).Before treatment,there was no significant difference in serum HE_(4) and CA125 levels between the two groups(P>0.05);After treatment,the levels of serum HE_(4) and CA125 in the two groups were lower than those before treatment,and the levels in the study group were significantly lower than those in the control group(P<0.05).Before treatment,there was no significant difference in blood flow classification between the two groups(P>0.05);After treatment,the blood flow grade of the study group was significantly better than that of the control group(P<0.05).There were no obvious adverse reactions during the treatment in both groups,and the liver and kidney functions and blood routine indexes were normal.Conclusion Mifepristone combined with Guizhi Fuling Capsule is effective in the treatment of uterine leiomyoma.It can improve hormone levels and blood flow indicators,reduce the risk of cancer,and there is no increase in adverse reactions during the treatment.It is safe and worthy of clinical promotion and application.